Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 17, 2018
Grant Date -
Jun 22, 2017
app pub date -
Dec 16, 2016
filing date -
Dec 16, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2016 Application Filing Year
- C07D Class
- 5513 Applications Filed
- 4516 Patents Issued To-Date
- 81.92 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 1 Citation Count
- C07D Class
- 46.30 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jan 17, 2026 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jan 17, 2030 |
